Vaporized Cannabis Administration and Co-Administration of Alcohol on Impairment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-26

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This human laboratory study will use cognitive, behavioral, and subjective measures to characterize impairment associated with co-use of alcohol and vaporized cannabis. Participants (n=32) will complete 7 double-blind, double-dummy outpatient sessions in randomized order. In each session, participants will self-administer placebo (0 mg THC) or active vaporized cannabis (5 or 25 mg THC, via a handheld vaporizer called the Mighty Medic) and a placebo drink (BAC 0.0%) or alcohol drink calculated to produce a breath alcohol concentration (BAC) of 0.05%. Participants will also complete a positive control session in which the participant administers placebo cannabis and alcohol at a target BAC of 0.08% (the legal threshold for driving impairment in most U.S. states).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Impact of Oral Cannabis Administration and Co-Administration of Alcohol on Impairment

NCT04931095

Cannabis Intoxication Alcohol Intoxication

COMPLETED PHASE1

Cannabidiol Effects on Blood Alcohol Level and Intoxication

NCT06105138

Alcohol Use Disorder

COMPLETED NA

Effects of THC on Alcohol Consumption and Neural Correlates of Reward

NCT06446479

Cannabis Use Disorder

RECRUITING PHASE2

Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder

NCT06512389

Alcohol Use Disorder

RECRUITING PHASE2

CBD for the Treatment of Alcohol Use Disorder

NCT04873453

Alcohol Use Disorder

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be conducted at the Johns Hopkins Behavioral Pharmacology Research Unit (BPRU). Participants will complete a screening visit, and, if eligible, will then complete 7 experimental drug administration sessions in randomized order where the participant will vaporize cannabis-containing capsules (or "pods") (containing 0, 5, or 25mg THC) with a drink that contains no alcohol or alcohol (alcohol-containing drinks will be calculated to produce a breath alcohol concentration, BAC, of 0.05%). There is also a positive control session where participants will vaporize placebo cannabis with an alcohol drink calculated to produce a BAC of 0.08%. Each session will last approximately 8 hours and will be separated by at least 48 hours to allow for sufficient drug washout. Participants may complete up to 2 sessions per week. Drugs will be administered in a double-blind and double-dummy fashion (i.e., participants will always receive both active or placebo cannabis and active or placebo alcohol). During each session, a battery of assessments including blood collection, subjective questionnaire administration, cognitive performance testing, and simulated driving will be conducted.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cannabis Intoxication Alcohol Intoxication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

All participants will complete all dose conditions (study arms) in a randomized order

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Double-blind (Participant, Outcomes Assessor), placebo controlled, and double-dummy

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo cannabis + placebo alcohol

Participants administer vaporized cannabis containing 0mg THC in combination with a placebo alcohol drink.

Group Type PLACEBO_COMPARATOR

Placebo Cannabis

Intervention Type DRUG

Placebo cannabis (i.e., water vapor) will be vaporized using the Mighty Medic.

Placebo Alcohol

Intervention Type DRUG

A non-alcoholic, placebo, flavored drink will be orally ingested.

Low dose cannabis with placebo alcohol

Participants administer vaporized cannabis containing 5mg THC in combination with a placebo alcohol drink.

Group Type EXPERIMENTAL

Cannabis

Intervention Type DRUG

Cannabis will be vaporized using the Mighty Medic

Placebo Alcohol

Intervention Type DRUG

A non-alcoholic, placebo, flavored drink will be orally ingested.

High dose cannabis with placebo alcohol

Participants administer vaporized cannabis containing 25mg THC in combination with a placebo alcohol drink.

Group Type EXPERIMENTAL

Cannabis

Intervention Type DRUG

Cannabis will be vaporized using the Mighty Medic

Placebo Alcohol

Intervention Type DRUG

A non-alcoholic, placebo, flavored drink will be orally ingested.

Low dose cannabis with low dose alcohol

Participants administer vaporized cannabis containing 5mg THC in combination with an alcohol drink (0.05 percent BAC).

Group Type EXPERIMENTAL

Cannabis

Intervention Type DRUG

Cannabis will be vaporized using the Mighty Medic

Alcohol

Intervention Type DRUG

Alcohol will be orally ingested via a flavored drink

High dose cannabis with low dose alcohol

Participants administer vaporized cannabis containing 25mg THC in combination with an alcohol drink (0.05 percent BAC).

Group Type EXPERIMENTAL

Cannabis

Intervention Type DRUG

Cannabis will be vaporized using the Mighty Medic

Alcohol

Intervention Type DRUG

Alcohol will be orally ingested via a flavored drink

Placebo cannabis + low dose alcohol

Participants administer vaporized cannabis containing 0mg THC in combination with an alcohol drink (0.05 percent BAC).

Group Type EXPERIMENTAL

Alcohol

Intervention Type DRUG

Alcohol will be orally ingested via a flavored drink

Placebo Cannabis

Intervention Type DRUG

Placebo cannabis (i.e., water vapor) will be vaporized using the Mighty Medic.

Placebo cannabis + high dose alcohol

Participants administer vaporized cannabis containing 0mg THC in combination with an alcohol drink (0.08 percent BAC).

Group Type EXPERIMENTAL

Alcohol

Intervention Type DRUG

Alcohol will be orally ingested via a flavored drink

Placebo Cannabis

Intervention Type DRUG

Placebo cannabis (i.e., water vapor) will be vaporized using the Mighty Medic.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cannabis

Cannabis will be vaporized using the Mighty Medic

Intervention Type DRUG

Alcohol

Alcohol will be orally ingested via a flavored drink

Intervention Type DRUG

Placebo Cannabis

Placebo cannabis (i.e., water vapor) will be vaporized using the Mighty Medic.

Intervention Type DRUG

Placebo Alcohol

A non-alcoholic, placebo, flavored drink will be orally ingested.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

THC Ethanol Placebo Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Have provided written informed consent
2. Be at least 21 years of age
3. Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests
4. Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at each study visit
5. Have not donated blood in the prior 30 days
6. Report at least 1 day of binge drinking in the past 3 months (greater than 4 or 5 drinks on a single occasion for women and men, respectively)
7. Report at least 1 use of cannabis in the past 3 years
8. Provide negative urine test for illicit drug use (excluding THC) and negative breath alcohol test (0% BAC) at screening and before study sessions
9. Report at least 1 lifetime instance of simultaneous alcohol and cannabis use
10. Current concomitant prescription medication use that may interact with the investigational study drug, including inhibitors and inducers of CYP2CP and CYP3A4 as well as highly-protein bound drugs and drugs with a narrow therapeutic index such as warfarin, cyclosporine, and amphotericin B

Exclusion Criteria

1. Psychoactive drug use (aside from cannabis, nicotine, alcohol, or caffeine) in the past month
2. History of or current evidence of significant medical condition that would put the participant at risk
3. Evidence of current psychiatric condition (MINI for DSM-V)
4. Meet criteria for severe alcohol use disorder (MINI for DSM-V)
5. CIWA-Ar score \> 9
6. Use of cannabis, on average, more than 3 days/week over past 3 months
7. Enrollment in another clinical trial or receiving of any drug as part of research within past 30 days
8. Shipley vocabulary score \<18 (corresponds to 5th grade reading level)

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes